It will be interesting to further study the differences of pharmacological and siRNA-based FAK inhibition in different tissues and situations of cellular interaction since FAK abrogation is a promising concept for future cancer therapies, whose molecular basis should be evaluated as precisely as possible [5]. This evidence concerns the gene PTK2 and cancer.